ankara escort porno delhi escort delhi escort

Scientific Publications

Dr. S.R. Burzynski and his associates continuously report new scientific information. The following is a list of publications that excludes articles published before 2010.

 

Targeted Therapy

  • Burzynski, S.R., Burzynski, G.S., Brookman, S.  A case of sustained objective response of recurrent/progressive diffuse intrinsic pontine glioma with phenylbutyrate and targeted agents. J Cancer Ther 2015;6:40-44.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Brookman, S.  Preliminary findings on the use of targeted therapy with pazopanib and other agents in combination with sodium phenylbutyrate in the treatment of glioblastoma multiforme. J Cancer Ther 2014;5:1423-1437.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Brookman, S.  Preliminary findings on the use of targeted therapy in combination with sodium phenylbutyrate in colorectal cancer after failure of second-line therapy – A potential strategy for improved survival. J Cancer Ther 2014;5:1270-1288.
  • Burzynski, S.R., Burzynski, G.S.  Long-term progression-free survival of recurrent glioblastoma multiforme treated with a combination of targeted agents: A case report. AT-14. Neuro Oncol 2014;16(Suppl. 5):v11.Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Brookman, S.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Brookman, S. Preliminary findings on the use of targeted therapy in combination with sodium phenylbutyrate in recurrent advanced pancreatic cancer – A potential strategy for improved survival. J Cancer Ther 2014;5:1072-1091.
  • Burzynski, S.R., Burzynski, G.S., Janicki, T.J.  Recurrent glioblastoma multiforme, a strategy for long-term survival. J Cancer Ther 2014;5:957-976.
  • Burzynski, S.R, Nagy-Kubove, E.Treatment of esthesioneuroblastoma and non-small cell lung cancer with phenylbutyrate.  Journal of Cancer Therapy 2011;2:518-522.

 

Clinic Trials 

  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S.  A phase II study of antineoplastons A10 and AS2-1 in adult patients with recurrent anaplastic astrocytoma. Final report (Protocol BT-15). Cancer ClinOncol 2015; in press.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A.  A phase II study of antineoplastons A10 and AS2-1 in patients with brainstem gliomas.  The report on non-diffuse intrinsic pontine glioma (Protocol BT-11). J Cancer Ther 2015;6:334-344.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A.  A phase II study of antineoplastons A10 and AS2-1 in adult patients with newly-diagnosed anaplastic astrocytoma. Final report (Protocol BT-08). Cancer ClinOncol 2015;4(1):28-38.
  • Burzynski, S.R., Janicki, T.J., Marszalek, A., Burzynski, G.S.  A phase II study of antineoplastons A10 and AS2-1 in patients with brainstem gliomas final report (Protocol BT-11). AT-15. Neuro Oncol 2014;16(Suppl. 5):v11.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S.  A phase II study of antineoplastons A10 and AS2-1 in adult patients with recurrent glioblastoma multiforme. Final report (Protocol BT-21). J Cancer Ther 2014;5:946-956.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A., Brookman, S.  A phase II study of antineoplastons A10 and AS2-1 in children with recurrent, refractory or progressive primary brain tumors. Final report (Protocol BT-22). J Cancer Ther 2014;5:977-988.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A.  A phase II study of antineoplastons A10 and AS2-1 in children with high-grade glioma. Final report (Protocol BT-06), and review of recent trials. J Cancer Ther 2014;5:565-577.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A. The response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma. Child’s Nervous System 2014;30(12):2051-2061.
  • Burzynski, S.R., Janicki, T., Burzynski, G., Marszalek, A.  A phase II study of antineoplastons A10 and AS2-1 in children with recurrent, refractory or progressive primary brain tumors based on protocol BT-22. CT-004.  Neuro-Oncology 2014;16(Suppl. 1):i10
  • Burzynski, G., Burzynski, S.R., Janicki, T., Marszalek, A.  A phase II study of antineoplastons A10 and AS2-1 in adult patients with recurrent glioblastoma multiforme based on protocol BT-21. NO-020.  Neuro-Oncology 2013;15(Suppl. 3):iii103.
  • Burzynski, S., Janicki, T., Burzynski, G., Marszalek, A.  A phase II study of antineoplastons A10 and AS2-1 in pediatric recurrent diffuse intrinsic pontine glioma. NO-021.  Neuro-Oncology 2013;15(Suppl. 3):iii103.
  • Janicki, T., Burzynski, S., Burzynski, G., Marszalek, A.  A phase II study of antineoplastons A10 and AS2-1 (ANP) in children with high-grade glioma (Protocol BT-06). NO-058.  Neuro-Oncology 2013;15(Suppl. 3):iii112.

 

Case Reports

  • Janicki, T.J., Burzynski, G.S., Burzynski, S.R.  Long-term survival (over 15 years) of pathologically confirmed recurrent glioblastoma multiforme: A case report. AT-28. Neuro Oncol 2014;16(Suppl. 5):v14-15.
  • Burzynski, G.S., Janicki, T.J., Marszalek, A., Burzynski, S.R.  Long-term survival (>20 years) of a child with brainstem glioma treated with antineoplastons A10 and AS2-1: A case report. PT-02. Neuro Oncol 2014;16(Suppl. 5):v175.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A.  Long-term survival (> 13 years) in a child with recurrent diffuse pontine gliosarcoma: the case report.  Journal of Pediatric Hematology/Oncology 2014;36(7):e433-e439. doi: 10.1097/MPH.0000000000000020.
  • Burzynski, G., Janicki, T., Burzynski, S.R., Marszalek, A.  Long-term survival (over 20 years) and pathologically confirmed complete response in pediatric anaplastic astrocytoma: a case report. HG-017.  Neuro-Oncology 2014;16(Suppl. 1):i44.
  • Janicki, T., Burzynski, S.R., Burzynski, G., Marszalek, A.  Long-term survival (over 20 years), complete response and normal childhood development in medulloblastoma (PNET) without recurrence: a case report. MB-039-020.  Neuro-Oncology 2014;16(Suppl. 1):i80.
  • Burzynski, S., Janicki, T., Burzynski, G., Marszalek, A.  Long-term survival (over 13 years) in a child with recurrent diffuse pontine gliosarcoma: A case report. NO-089.  Neuro-Oncology 2013;15(Suppl. 3):iii120.

 

Review Articles

  • Burzynski, S.R.  Stanislaw R. Burzynski, MD, PhD: Novel cancer research and the fight to prove its worth. Alternative Therapies in Health and Medicine 2012;18(3):54-61.

 

Basic Science

  • Burzynski, S.R., Patil, S.S.  The effect of antineoplastons A10 and AS2-1 and metabolites of sodium phenylbutyrate on gene expression in glioblastoma multiforme. J Cancer Ther 2014;5:929-945.

  • Aliev, G., Burzynski, G., Ashraf, G.M., Jabir, N.R., Cacabelos, R., Benberin, V.V., Burzynski, S.R.  Implication of oxidative stress-induced oncogenic signaling pathways as a treatment strategy for neurodegeneration and cancer.  SystBiol Free Rad Antioxid 2014; 2325-2347; DOI: 10.1007/978-3-642-30018-9.
  • Aliev, G., Palacios, H.H., Cacabelos, P., Cacabelos, R., Burzynski, G., Burzynski, S.R.  Mitochondria specific antioxidants and their derivatives in the context of the drug development for neurodegeneration and cancer.   Drug Designing 2013;2(1):103.
  • Patil, S.S., Mrowczynski, E., Grela, K., Burzynski, S.R.  Phenylacetylglutaminate in combination with phenylbutyrate effectively inhibits growth of brain tumor cells in vitro.  Neuro-Oncology 2012;14(Suppl. 3):iii16.
  • Patil, S.S., Burzynski, S.R., Mrowczynski, E., Grela, K., Chittur, S.V.  Phenylacetylglutaminate and phenylacetate in combination upregulate VDUP1, cause cell cycle blockade and apoptosis in U87 glioblastoma cells.  Journal of Cancer Therapy 2012;3:192-200.

 

 

 

slide1 slide3

Sophia

Brain tumor
Cancer free since 2003
Read her story

James Treadwell

Brain cancer
Cancer free for 5 years
Read his story
istanbul escort istanbul escort